157 related articles for article (PubMed ID: 9153530)
1. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
[TBL] [Abstract][Full Text] [Related]
2. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging.
Hartung HP; Reiners K; Archelos JJ; Michels M; Seeldrayers P; Heidenreich F; Pflughaupt KW; Toyka KV
Ann Neurol; 1995 Aug; 38(2):186-93. PubMed ID: 7544573
[TBL] [Abstract][Full Text] [Related]
3. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis.
Rieckmann P; Altenhofen B; Riegel A; Baudewig J; Felgenhauer K
Ann Neurol; 1997 Mar; 41(3):326-33. PubMed ID: 9066353
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
Gonzalez-Scarano F; Grossman RI; Galetta S; Atlas SW; Silberberg DH
Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
[TBL] [Abstract][Full Text] [Related]
5. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
[TBL] [Abstract][Full Text] [Related]
6. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
Trojano M; Defazio G; Avolio C; Paolicelli D; Giuliani F; Giorelli M; Livrea P
J Neurovirol; 2000 May; 6 Suppl 2():S47-51. PubMed ID: 10871785
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
Graber J; Zhan M; Ford D; Kursch F; Francis G; Bever C; Panitch H; Calabresi PA; Dhib-Jalbut S
J Neuroimmunol; 2005 Apr; 161(1-2):169-76. PubMed ID: 15748956
[TBL] [Abstract][Full Text] [Related]
8. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.
Rieckmann P; Altenhofen B; Riegel A; Kallmann B; Felgenhauer K
Mult Scler; 1998 Jun; 4(3):178-82. PubMed ID: 9762670
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Jensen J; Krakauer M; Sellebjerg F
Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
11. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.
Lou J; Gasche Y; Zheng L; Giroud C; Morel P; Clements J; Ythier A; Grau GE
Lab Invest; 1999 Aug; 79(8):1015-25. PubMed ID: 10462039
[TBL] [Abstract][Full Text] [Related]
14. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients.
Alexiou D; Karayiannakis AJ; Syrigos KN; Zbar A; Sekara E; Michail P; Rosenberg T; Diamantis T
Am J Gastroenterol; 2003 Feb; 98(2):478-85. PubMed ID: 12591072
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging.
Grossman RI; Braffman BH; Brorson JR; Goldberg HI; Silberberg DH; Gonzalez-Scarano F
Radiology; 1988 Oct; 169(1):117-22. PubMed ID: 3420246
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
[TBL] [Abstract][Full Text] [Related]
18. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor synergistically enhances induction of E-selectin by tumor necrosis factor-alpha.
Stannard AK; Khurana R; Evans IM; Sofra V; Holmes DI; Zachary I
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):494-502. PubMed ID: 17170373
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
